ReviewInternational journal of retina and vitreous2024
Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights.
Review in International journal of retina and vitreous, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Contrast Sensitivity Impairment in Diabetic Retinopathy: Clinical and Structural Correlates.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.Eye (London, England) · 2026Review
- Generative Artificial Intelligence-Driven Voice Assistance for Patient Education in Ophthalmology.JAMA ophthalmology · 2026Article
- Efficacy and safety of ranibizumab, aflibercept, and conbercept in the treatment of diabetic macular edema: a retrospective comparative study.Scientific reports · 2026Article
- Environmental Exposures and Oxidative Stress in Retinal and Optic Nerve Diseases: Mechanisms, Consequences, and Therapeutic Opportunities.Antioxidants (Basel, Switzerland) · 2026Review
- Quantifying the direct costs of diabetic retinopathy in a mixed healthcare system: a hospital-based study from governmental and patient perspectives.Cost effectiveness and resource allocation : C/E · 2026Article
- A Hierarchical Deep Learning Architecture for Diagnosing Retinal Diseases Using Cross-Modal OCT to Fundus Translation in the Lack of Paired Data.Journal of imaging · 2026Article
- Clinical and optical coherence tomography predictors of spontaneous resolution of diabetic macular edema: incremental value of the subfoveal large choroidal vessel layer thickness ratio.Frontiers in medicine · 2026Article
- Patient and Physician Perspectives on the Management of Diabetic Macular Edema.Ophthalmology and therapy · 2026Article
- Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort.Frontiers in endocrinology · 2026Article
- Ten-Year Trends of Intravitreal Injection in South Korea Using the Health Insurance Review and Assessment Service Data.Korean journal of ophthalmology : KJO · 2025Observational
- Diagnostic Accuracy of Artificial Intelligence in Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Formulation of α-Linolenic Acid-Based Microemulsions for Age-Related Macular Degeneration: Physicochemical Tests and HET-CAM Assays for Anti-Angiogenic Activities.Medicina (Kaunas, Lithuania) · 2025Article
- Combined thermal and mild electrical stimulations modulate heat shock protein and VEGF in retinal pigment epithelial cells under high glucose.BMC research notes · 2025Article
- Increased survival reveals new paradigms in diabetic macular edema among patients with type 1 diabetes.Endocrine · 2025Article
- Regulation of toll-like receptor signaling pathways in age-related eye disease: from mechanisms to targeted therapeutics.Inflammopharmacology · 2025Review
- Efficacy of fluocinolone acetonide implant in diabetic macular edema patients previously treated with dexamethasone implant: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Article
- Modulation of Oxidative Stress in Diabetic Retinopathy: Therapeutic Role of Natural Polyphenols.Antioxidants (Basel, Switzerland) · 2025Review
- Allergic Contact Dermatitis to Povidone-Iodine and Systemic Contact Dermatitis to Chloramphenicol, Used During Intravitreal Injection of Bevacizumab, an Anti-Vascular Endothelial Growth Factor.Contact dermatitis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most common health concerns disturbing people within working years globally is diabetes mellitus (DM). One well-known consequence of DM is vascular damage, which can manifest as macro- and microangiopathy affecting the ocular retina. Therefore, Diabetic macular edema (DME) is a major sight-threatening complication of diabetic retinopathy (DR) worldwide. It is the most prevalent cause of significant vision impairment in diabetic patients. Long-term vision loss can be avoided by following early DME treatment guidelines in everyday life. Hence, there are various therapeutic approaches for DME management. Currently, the first-line treatment for DME is anti-VEGF family drugs, such as ranibizumab, brolucizumab, bevacizumab, and aflibercept. Nevertheless, relapses of the disease, inadequate response, and resistance during anti-VEGF therapy are still seen because of the intricate pathophysiological foundation of the disease. Consequently, there is an excellent requirement for therapeutic approaches to advance and become better at controlling diseases more satisfactorily and require fewer treatments overall. We conducted a thorough literature search in the current review to present a comprehensive overview of the primary data about the current DME therapeutic agents. We also covered the novel advances in DME management and probable future treatments being investigated and developed. This review recommended that Large clinical trials should afford sufficient evidence to support these innovative treatment modalities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.